Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis.

Angiogenesis/angiostasis regulated by hypoxia inducible factor-1A (HIF-1A)/vascular endothelial growth factor (VEGF)/inhibitor of growth protein 4 (ING-4) axis may be crucial for the course and outcome of sarcoidosis. Overexpression of angiogenic factors (activation of VEGF through HIF-1A) may predispose to chronic course and lung fibrosis, whereas immunoangiostasis (related to an overexpression of inhibitory ING-4) may be involved in granuloma formation in early sarcoid inflammation, or sustained or recurrent formation of granulomas. In this work we investigated gene expression of HIF-1A, VEGF and ING-4 in bronchoalveolar fluid (BALF) cells and in peripheral blood (PB) lymphocytes of sarcoidosis patients (n=94), to better understand mechanisms of the disease and to search for its biomarkers. The relative gene expression level (RQ value) was analyzed by qPCR. The results were evaluated according to the presence of lung parenchymal involvement (radiological stage I vs. II-IV), acute vs. insidious onset, lung function tests, calcium metabolism parameters, percentage of lymphocytes (BALL%) and BAL CD4+/CD8+ in BALF, age, and gender. In BALF cells, the ING-4 and VEGF RQ values were increased, while HIF-1A expression was decreased. In PB lymphocytes all studied genes were overexpressed. Higher expression of HIF-1A in PB lymphocytes of patients with abnormal spirometry, and in BALF cells of patients with lung volume restriction was found. VEGF gene expression in BALF cells was also higher in patients with abnormal spirometry. These findings were in line with previous data on the role of HIF-1A/VEGF/ING-4 axis in the pathogenesis of sarcoidosis. Up-regulated HIF-1A and VEGF genes are linked to acknowledged negative prognostics.

[1]  A. Fal,et al.  [Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods]. , 2011, Pneumonologia i alergologia polska.

[2]  T. Sugai,et al.  Heterogeneous characteristics of lymphatic microvasculatures associated with pulmonary sarcoid granulomas. , 2013, Annals of the American Thoracic Society.

[3]  N. Siafakas,et al.  Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. , 2006, Chest.

[4]  K. Müller,et al.  Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis , 1998, Virchows Archiv.

[5]  D. Ziora,et al.  [Proangiogenic cytokines (bFGF and VEGF) in BALF from two different lung segments examined by high resolution computed tomography (HRCT) in patients with sarcoidosis]. , 2000, Pneumonologia i alergologia polska.

[6]  F. Bonella,et al.  Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease , 2009, Respiration.

[7]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[8]  W. Młynarski,et al.  Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis. , 2014, Polskie Archiwum Medycyny Wewnetrznej.

[9]  U. Demkow,et al.  Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function , 2010, European journal of medical research.

[10]  陶仲为 Sarcoidosis , 2009 .

[11]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  A. Prasse,et al.  Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. , 2011, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[13]  J. Tidball,et al.  Mechanical loading regulates expression of talin and its mRNA, which are concentrated at myotendinous junctions. , 1998, American journal of physiology. Cell physiology.

[14]  A. Lazarus Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. , 2009, Disease-a-month : DM.

[15]  G. Semenza,et al.  Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. , 1998, The American journal of physiology.

[16]  D. Pastuszak-Lewandoska,et al.  TGF-β and SMADs mRNA Expression in Pulmonary Sarcoidosis. , 2015, Advances in experimental medicine and biology.

[17]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[18]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis , 1999 .

[19]  Y. Fukuchi,et al.  Serum Vascular Endothelial Growth Factor as a Possible Prognostic Indicator in Sarcoidosis , 2003, Lung.

[20]  M. Déry,et al.  Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. , 2005, The international journal of biochemistry & cell biology.

[21]  A. Karameris,et al.  Expression of Hypoxia-Inducible Factor (HIF)-1a-Vascular Endothelial Growth Factor (VEGF)-Inhibitory Growth Factor (ING)-4- axis in sarcoidosis patients , 2012, BMC Research Notes.

[22]  G. Semenza,et al.  HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. , 2011, American journal of respiratory and critical care medicine.

[23]  M. Frid,et al.  Hypoxia-induced Pulmonary Vascular Remodeling Cellular and Molecular Mechanisms Reviews , 2022 .

[24]  R. Pedeux,et al.  The ING tumor suppressor genes: status in human tumors. , 2014, Cancer letters.

[25]  D. Spandidos,et al.  Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study , 2010, Clinical & developmental immunology.